Active Ingredient History
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, and lipid modulator PEA has been studied in in vitro and in vivo systems using exogenously added or dosed compound; there is evidence that it binds to a nuclear receptor, through which it exerts a variety of biological effects, some related to chronic inflammation and pain. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anosmia (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Chronic Pain (Phase 4)
COVID-19 (Phase 4)
Dermatitis, Atopic (Phase 2/Phase 3)
Fibromyalgia (Phase 4)
Glaucoma (Phase 2)
Irritable Bowel Syndrome (Phase 2)
Migraine Disorders (Phase 3)
Olfaction Disorders (Phase 4)
Patient Compliance (Phase 4)
Sleep Apnea, Obstructive (Phase 2)
Tourette Syndrome (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue